<DOC>
	<DOCNO>NCT03064906</DOCNO>
	<brief_summary>To assess safety performance Insulet AP ( artificial pancreas ) system , use Omnipod® insulin management system , Dexcom G4 Share® AP System personalize model predictive control algorithm adult type 1 diabetes consume high fat meal undertake moderate intensity exercise .</brief_summary>
	<brief_title>Insulet Artificial Pancreas Evaluating Meal Performance Moderate Exercise ( IDE2 )</brief_title>
	<detailed_description>The two-part study schedule consist 7±1 day outpatient , open-loop phase , follow one 54-hour , hybrid closed-loop phase conduct supervise CRC hotel/rental house setting .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Age time consent 18.0 65.0 year 2 . Diagnosed type 1 diabetes least one year . Diagnosis base investigator 's clinical judgment . 3 . Total daily dose ( TDD ) insulin ≥0.3 units/kg/day A1C &gt; 6 % screen 4 . Currently use insulin pump U100 rapidacting insulin analog pump therapy least 6 month prior study start 5 . Willing use study CGM device duration study 6 . Willing use Omnipod® Insulin Management System study 7 . Willing perform fingerstick BG test studyapproved glucose meter frequency specify study protocol 8 . Willing abide meal recommendation breakfast , lunch dinner study 9 . Willing participate moderate intensity exercise 45 minute take part Option B 10 . Willing refrain use acetaminophen supplemental vitamin C ( &gt; 2000 mg/daily ) entire duration participation study 11 . Willing able sign Informed Consent Form ( ICF ) 1 . A1C &gt; 10 % screen visit 2 . One episodes severe hypoglycemia require emergency room ( ER ) visit hospitalization within past 6 month 3 . Hypoglycemic unawareness determine score ≥4 `` R '' responses Clarke Questionnaire 4 . One episodes diabetic ketoacidosis require ER visit hospitalization within past 6 month 5 . Used noninsulin antidiabetic medication within last 30 day 6 . Pregnant lactating , woman childbearing potential acceptable form birth control ( acceptable include abstinence , condom , oral/injectable contraceptive , IUD implant ) 7 . Dermatological condition propose sensor wear sit investigator 's opinion could preclude ability wear Pod and/or Dexcom sensor 8 . Current known history cardiovascular disease , arrhythmia , myocardial infarction ( MI ) stroke . An electrocardiogram ( ECG ) must obtain within 6 month . 9 . Currently undergo systemic treatment steroid immunosuppressive medication 10 . Current illness would interfere participation study 11 . Currently participate another clinical study use investigational drug device 12 . Recent ( within precede 30 day ) participation clinical study use investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>T1D , Omnipod</keyword>
</DOC>